Verastem reports early trial data for KRAS G12D cancer drug VS-7375

June 23, 2026 4:01 PM

Verastem Oncology (Nasdaq: VSTM) released preliminary data from its ongoing TARGET-D 101 Phase 1/2 clinical trial evaluating VS-7375, an investigational ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found